SARASOTA, FL -- (MARKET WIRE) -- October 05, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that two products being developed by Biofrontera AG, a company in Germany in which DNAPrint Genomics owns an 18.3% stake, have been approved for the next stages of their respective clinical trial processes. The products are Biofrontera's BF-200 ALA treatment for actinic keratosis (precancerous and cancerous skin lesions), its lead product, and BF-derm1, a treatment for chronic urticaria (hives).
